Trial Profile
MAXIMISE (Managing AXIal Manifestations in PsorIatic Arthritis With SEcukinumab), a Randomized, Double-blind, Placebo-controlled, Multicenter, 52-week Study to Assess the Efficacy and Safety of Secukinumab 150 mg or 300 mg s.c. in Participants With Active Psoriatic Arthritis and Axial Skeleton Involvement Who Have Inadequate Response to Non-steroidal Anti-inflammatory Drugs (NSAIDs)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Apr 2023
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Axial spondyloarthritis; Psoriatic arthritis
- Focus Registrational; Therapeutic Use
- Acronyms MAXIMISE
- Sponsors Novartis; Novartis Pharmaceuticals
- 24 Apr 2023 Results published in the Rheumatology
- 14 Nov 2022 Results of post hoc (n=2504) pooled analysis from the FUTURE 2, 3, 4, 5 and MAXIMISE studies investigated the impact of different levels of HU, and history of gout/uric acid lowering therapy (ULT) on pts with PsA in terms of demographics, clinical characteristics, comorbidities, and clinical response to secukinumab over 1 year, presented at the ACR Convergence 2022.
- 04 Jun 2022 Results of post hoc analysis included pooled data from PsA pts enrolled in the FUTURE 2-5 and MAXIMISE phase, evaluating the impact of HU on PsA in terms of clinical presentation, severity, comorbidities, and response to secukinumab (SEC) over 1-year, presented at the 23rd Annual Congress of the European League Against Rheumatism